Biotech Investors: Believing the Dream, Rewarding Phase III IPOs
This article was originally published in Start Up
Executive Summary
Valuation Watch: our analysis of US biotech companies that have gone public in the 2003-04 window shows that having a late-stage development project offers private investors the best step-ups.
You may also be interested in...
IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?
Valuation Watch: an analysis of pre-money step ups for the 2003-04 biotech IPO window demonstrates that public investors are favoring companies in some therapeutic areas over companies in other areas. CNS and jump-start technologies, for example, are doing well.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.